Ajanta Pharma Limited promoter, Ravi Agrawal, has completed a strategic restructuring of share pledges involving 935,000 equity shares. The activity, conducted in late March 2026, involved releasing existing encumbrances to facilitate re-financing and subsequently creating new pledges. This shift in collateral structure is part of the promoter’s ongoing financial management activities, with total pledged shares maintained to support institutional financing arrangements.
Pledge Restructuring Details
On March 25, 2026, and March 27, 2026, Ravi Agrawal (as trustee of the Ravi Agrawal Trust) undertook a series of transactions to re-finance his holdings in Ajanta Pharma. The promoter released a total of 935,000 equity shares that were previously held as collateral by lenders, including Bajaj Finance Ltd, Aditya Birla Capital Ltd, RBL Bank, and HSBC InvestDirect Financial Services (India) Limited.
Strategic Financial Realignment
Following the release, an equivalent volume of 935,000 equity shares was pledged to Tata Capital Limited, RBL Bank, Bajaj Finance Ltd, and Aditya Birla Capital Ltd. The primary driver for this activity was identified as Re-Financing, while the initial release was prompted by an Excess Pledge position. These movements reflect active management of personal debt facilities while maintaining significant promoter interest in the company.
Current Holding Profile
The promoter group continues to maintain a substantial stake in the company. Following these transactions, the post-event encumbered holding for the Ravi Agrawal Trust stands at 6,063,920 shares, representing approximately 4.85% of the total share capital. The broader promoter group, including entities like Gabs Investments Pvt Ltd and Yogesh Agrawal Trust, remains committed to their long-term position within Ajanta Pharma Limited.
Source: BSE
